A key pathology of Alzheimer’s disease (AD) is amyloid β (Aβ) accumulation which triggers synaptic impairments and neuronal death. Metabolic disruption is common in AD and recent evidence implicates impaired leptin function in AD. Thus the leptin system may be a novel therapeutic target in AD. Indeed, leptin has cognitive enhancing properties and it prevents the aberrant effects of Aβ on hippocampal synaptic function and neuronal viability. However as leptin is a large peptide, development of smaller leptin-mimetics may be the best therapeutic approach. Thus, we have examined the cognitive enhancing and neuroprotective properties of known bioactive leptin fragments. Here we show that the leptin (116-130) fragment, but not leptin (22-56), mirrored the ability of leptin to promote AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Administration of leptin (116-130) also mirrored the cognitive enhancing effects of leptin as it enhanced performance in episodic-like memory tests. Moreover, leptin (116-130) prevented hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. These findings establish further the importance of the leptin system as a therapeutic target in AD.
|Number of pages||14|
|Early online date||6 Sept 2016|
|Publication status||Published - 6 Sept 2016|
- Alzheimer's disease
- amyloid beta
- AMPA receptor trafficking
- episodic memory
- synaptic plasticity
FingerprintDive into the research topics of 'A Leptin Fragment Mirrors the Cognitive Enhancing and Neuroprotective Actions of Leptin'. Together they form a unique fingerprint.
- Systems Medicine - Professor (Teaching and Research) & Professor of Cellular Neuroscience